ROBOSENSE
23.4.2021 20:02:05 CEST | Business Wire | Press release
During the Shanghai Auto Show, RoboSense (https://robosense.ai/ ), a smart and automotive LiDAR system provider, and Webasto (https://www.webasto-group.com/ ), the global Top 100 automotive supplier and market leader for roof systems, announced cooperation on the Smart Roof Sensor Module that integrated with RoboSense automotive-grade MEMS LiDAR RS-LiDAR-M1 for Level 3 to Level 5 autonomous driving vehicles, largely simplifying the structure and mounting process of conventional sensor sets of self-driving vehicles and ensures advanced safety perception.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210423005484/en/
Through this strategic cooperation, Webasto is committed to seamlessly embedding the RoboSense M1, camera and other sensor systems to the panoramic roof of vehicles to provide safer and more reliable environment perception information at the smallest possible space in the roof. The solution allows different roof systems to be mounted on the vehicle body, creating greater flexibility for the development of autonomous vehicles.
As the world’s market leader, Webasto offers the broadest product range of high-quality roof systems. The rooftop design not only enables the integration of sensor systems but also adopts highly rigid transparent material and the openable top function, which creates the feeling of freedom for the passengers.
The RoboSense M1 boasts 125 ultra-high resolution scanning beams, ultra-wide FOV of 120°*25°, and a maximum detection range of 200m (150M@10%). At present, the M1(thickness 45mm, depth 108mm, width 110mm) is the thinnest solid-state LiDAR on the market. At the highest point of the vehicle, the M1’s unique mounting position in the smart roof module gives it the vantage point of view, which can greatly improve the detection ability of the perception system and ensure the safe and stable operation of the autonomous driving systems. Moreover, it costs less fuel consumption/NEDC mileage than other LiDAR products.
“Webasto looks for the most compact and state-of-the-art perception sensing systems on the market desired by our customers for roof-mounted integration. The RoboSense M1 meets these criteria and provides both promising size and suitability for roof integration”, says Brad Tang, Strategy & Product Planning Manager at Webasto.
Mark Qiu, RoboSense Executive President and Co-Partner says, " By combining the most mature roof module technology and the most compact size MEMS solid-state LiDAR, we provide the elegant, easy-to-integrate and one-stop smart roof solution with safety perception function to OEMs and end-users.”
The SOP version of M1 has fully met the OEM’s all automotive-grade requirements.
- M1 has successfully solved point cloud’s “corner cases” including high reflectivity objects, near-field obstacles, strong ambient light (direct sunlight), and interference from other LiDAR sensors, etc.
- M1 successfully passed the automotive-grade verification tests include mechanical and vibration, shock, EMC electromagnetic compatibility, human eye safety, chemical anti-corrosion, salt spray, high and low-temperature storage and operation, etc.
- Moreover, RoboSense has established China’s first automotive-grade solid-state LiDAR production line and would start mass production and delivery in Q2 2021.
About RoboSense
Founded in 2014, RoboSense (Suteng Innovation Technology Co., Ltd.) is the leading provider of Smart LiDAR Sensor Systems incorporating LiDAR sensors, AI algorithms and IC chipsets, that transform conventional 3D LiDAR sensors to full data analysis and comprehension systems. https://robosense.ai/
About Webasto
The Webasto Group is a global innovative systems partner to almost all automobile manufacturers and among the top 100 suppliers in this industry sector. The company’s product portfolio comprises a broad range of roof and heating systems for every type of vehicle and all drive types as well as battery systems and charging solutions. http://www.webasto-group.com/ or http://www.twitter.com/WebastoGroup
View source version on businesswire.com: https://www.businesswire.com/news/home/20210423005484/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom